Journal article
Machine Perfusion and Mitigating Risk Factors for Delayed Graft Function in Pediatric Kidney Transplant Recipients
Pediatric transplantation, Vol.30(8), e70429
08/2026
DOI: 10.1111/petr.70429
PMID: 42576566
Abstract
Kidney transplantation confers prolonged and improved quality of life versus dialysis for patients with end-stage kidney disease (ESKD). Delayed graft function (DGF) increases the risk of allograft rejection and decreases allograft survival. In adults, prolonged warm (WIT) and cold ischemia time (CIT) increase risk of DGF, and machine perfusion (MP) during organ transportation reduces this risk. However, there is a paucity of data regarding risk factors for DGF in children.
We retrospectively evaluated risk and protective factors for DGF in patients aged 18 months to 21 years who underwent kidney transplantation at Cincinnati Children's Hospital Medical Center between 11/1/2017 and 11/30/2021. DGF was defined as receiving dialysis within 7 days post-transplant.
Nine of 89 (10%) patients developed DGF. Patients with DGF had longer median WIT (49 IQR: 44-57 vs. 37 min IQR: 30-43; p = 0.002) and were more likely to have received a deceased donor (DD) allograft (p = 0.04, RR1.7 (95% CI: 1.2-2.4)). There was no difference in CIT between those who did and did not experience DGF (464 IQR:329-788 vs. 271 min. IQR:271-788; p = 0.16). No patients who received DD-MP kidneys developed DGF. DGF in recipients of DD-non-MP kidneys had longer WIT (53 IQR: 43-57 vs. 36 min. IQR: 30-44; p < 0.009).
Increased WIT increases the risk of DGF in pediatric kidney transplant recipients, whereas MP appears to be protective against DGF and may ameliorate the adverse effect of CIT. DGF was rare in the cohort and further studies are necessary due to the low incidence of DGF.
Details
- Title: Subtitle
- Machine Perfusion and Mitigating Risk Factors for Delayed Graft Function in Pediatric Kidney Transplant Recipients
- Creators
- Kyle A Merrill - University of IowaCassie Kirby - Cincinnati Children's Hospital Medical CenterTeresa Ambrosino - Cincinnati Children's Hospital Medical CenterCharles D Varnell Jr - Cincinnati Children's Hospital Medical CenterAlexander Bondoc - University of CincinnatiLakhmir Chawla - VA San Diego Healthcare SystemStuart L Goldstein - Cincinnati Children's Hospital Medical CenterDavid K Hooper - Cincinnati Children's Hospital Medical Center
- Resource Type
- Journal article
- Publication Details
- Pediatric transplantation, Vol.30(8), e70429
- DOI
- 10.1111/petr.70429
- PMID
- 42576566
- NLM abbreviation
- Pediatr Transplant
- ISSN
- 1399-3046
- eISSN
- 1399-3046
- Publisher
- Wiley
- Grant note
- BioPorto Diagnostics Inc Calcimedica Vantive SeaStar Medical Talphera Otsuka
K.A.M. reports consulting relationship with BioPorto Diagnostics Inc. and is KOL for Vantive, INC. S.L.G. reports consulting income and grant funding from BioPorto Diagnostics Inc., which markets ProNephroAKI. S.L.G. also reports consulting income and grant funding from Calcimedica, Vantive, SeaStar Medical, Talphera, and Otsuka. S.L.G. has additional consulting income from Silver Creek Pharmaceuticals and TRiNDS Inc. S.L.G. is a stockholder of MediBeacon Inc. During conduct and writing of this research, D.K.H. reports consulting income from BioPorto Diagnostics Inc., Alynylam Pharmaceuticals, Kaneka America, and Maximus Federal. D.K.H. currently reports consulting income from AssureCare LLC. D.K.H. was at Cincinnati Children's Hospital and University of Cincinnati at the time this research was con-ducted. He is now faculty at the University of Utah Spencer Fox Eccles School of Medicine, Salt Lake City, Utah.
- Language
- English
- Date published
- 08/2026
- Academic Unit
- Nephrology, Dialysis and Transplantation; Stead Family Department of Pediatrics
- Record Identifier
- 9985218425402771
Metrics
2 Record Views